Inovio Pharmaceuticals (INO) Q4 2025 earnings summary

Executive summary

• BLA for INO-3107 accepted by FDA for review under the Accelerated Approval Program, with a PDUFA target date of October 30, 2026; FDA raised questions about eligibility for accelerated approval, with a meeting pending.

• Commercial preparations for INO-3107 are well underway, including resource optimization, launch readiness, and go-to-market planning.

• Pipeline progress includes partnerships for glioblastoma and rare disease programs, leveraging DNA medicine platform and next-generation technologies.

• Published positive immunological and long-term clinical data for INO-3107 in peer-reviewed journals, showing reduced need for surgery in RRP patients.

• Focused on commercial readiness for INO-3107, including market research, pricing strategy, and building commercial infrastructure.

Financial highlights

• Cash, cash equivalents, and short-term investments totaled $58.5 million at year-end 2025, down from $94.1 million at year-end 2024.

• Operating expenses for Q4 2025 were $17.5 million, down from $20.5 million in Q4 2024; full-year operational expenses decreased 23% to $86.9 million.

• Net income for Q4 2025 was $3.8 million, primarily due to a $21.2 million non-cash gain on warrant liability adjustment; full-year 2025 net loss was $84.9 million.

• Net loss per share for FY2025 was $(1.81), improved from $(3.95) in 2024.

• No debt and projected cash runway into Q4 2026.

Outlook and guidance

• Focus remains on advancing INO-3107 toward FDA approval and commercial launch, with cash runway expected to last into Q4 2026, not including potential capital raises.

• Pipeline advancement for other candidates and next-generation DNA medicines is contingent on INO-3107 approval and available resources.